文献速递儿童感染儿童呼吸

儿童和青少年COVID-19的30天结局:一项国际研究

Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience.
PubMed 文献 · Pediatrics · 2021-05-28

该国际网络队列研究使用欧洲初级保健记录、韩国和美国索赔数据及医院数据库,纳入2020年1月至6月诊断和/或住院的年龄<18岁儿童和青少年。结果显示COVID-19住院率0.3%-1.3%,30天病死率极低,但肺炎、低氧血症等30天结局较流感更常见。

要点

  • COVID-19住院患儿中神经发育障碍、心脏病和癌症等合并症较门诊诊断患儿更常见。
  • 呼吸困难、毛细支气管炎、嗅觉丧失和胃肠道症状在COVID-19中较流感更常见。
  • COVID-19诊断队列住院率0.3%-1.3%,30天病死率极低。

核心结论

  • 儿童和青少年COVID-19病死率极低,但住院、低氧血症和肺炎等并发症较流感更常见。

研究设计与样本

  • 国际网络队列研究,使用欧洲初级保健记录(法国、德国、西班牙)、韩国索赔、美国索赔及医院数据库。
  • 纳入2020年1月至6月年龄<18岁诊断和/或住院的COVID-19儿童和青少年。

主要发现

  • 住院COVID-19患儿中神经发育障碍、心脏病和癌症较诊断COVID-19患儿更常见。
  • 呼吸困难、毛细支气管炎、嗅觉丧失和胃肠道症状在COVID-19中较流感更常见。
  • COVID-19诊断队列住院率为0.3%至1.3%,30天病死率极低(每数据库n<5)。
  • COVID-19的30天结局包括肺炎和低氧血症较流感更频繁。

关键数值与推荐

  • 住院COVID-19治疗包括超说明书用药(<10%)及辅助治疗:全身性糖皮质激素(6.8%-7.6%)、法莫替丁(9.0%-28.1%)、抗血栓药如阿司匹林(2.0%-21.4%)、肝素(2.2%-18.1%)和依诺肝素(2.8%-14.8%)。

临床怎么用

  • 呼吸困难、嗅觉丧失和胃肠道症状可帮助鉴别COVID-19与流感。
  • 儿童COVID-19住院管理中使用多种药物,包括超说明书用药和辅助治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To characterize the demographics, comorbidities, symptoms, in-hospital treatments, and health outcomes among children and adolescents diagnosed or hospitalized with coronavirus disease 2019 (COVID-19) and to compare them in secondary analyses with patients diagnosed with previous seasonal influenza in 2017-2018. METHODS: International network cohort using real-world data from European primary care records (France, Germany, and Spain), South Korean claims and US claims, and hospital databases. We included children and adolescents diagnosed and/or hospitalized with COVID-19 at age <18 between January and June 2020. We described baseline demographics, comorbidities, symptoms, 30-day in-hospital treatments, and outcomes including hospitalization, pneumonia, acute respiratory distress syndrome, multisystem inflammatory syndrome in children, and death. RESULTS: A total of 242 158 children and adolescents diagnosed and 9769 hospitalized with COVID-19 and 2 084 180 diagnosed with influenza were studied. Comorbidities including neurodevelopmental disorders, heart disease, and cancer were more common among those hospitalized with versus diagnosed with COVID-19. Dyspnea, bronchiolitis, anosmia, and gastrointestinal symptoms were more common in COVID-19 than influenza. In-hospital prevalent treatments for COVID-19 included repurposed medications (<10%) and adjunctive therapies: systemic corticosteroids (6.8%-7.6%), famotidine (9.0%-28.1%), and antithrombotics such as aspirin (2.0%-21.4%), heparin (2.2%-18.1%), and enoxaparin (2.8%-14.8%). Hospitalization was observed in 0.3% to 1.3% of the cohort diagnosed with COVID-19, with undetectable (n < 5 per database) 30-day fatality. Thirty-day outcomes including pneumonia and hypoxemia were more frequent in COVID-19 than influenza. CONCLUSIONS: Despite negligible fatality, complications including hospitalization, hypoxemia, and pneumonia were more frequent in children and adolescents with COVID-19 than with influenza. Dyspnea, anosmia, and gastrointestinal symptoms could help differentiate diagnoses. A wide range of medications was used for the inpatient management of pediatric COVID-19.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. Duarte-Salles T, Vizcaya D, Pistillo A, et al. Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience. Pediatrics. 2021. PMID: 34049958. doi:10.1542/peds.2020-042929

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。